Understanding how TET2 affects CAR T cell function in cancer treatment
Mechanisms of TET2-dependent control of CAR T cell fate determination and antitumor function
This study is looking at how a specific enzyme called TET2 affects the success of CAR T cell therapy, which is a treatment that helps your own immune cells fight cancer, to find ways to make this therapy even better for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10897796 on NIH RePORTER |
What this research studies
This research investigates the role of the TET2 enzyme in the effectiveness of CAR T cell therapy, a treatment where a patient's own T cells are modified to attack cancer cells. By examining how TET2 influences T cell differentiation and function, the study aims to uncover mechanisms that could enhance the potency of CAR T cells. The approach involves analyzing DNA modifications and chromatin structure to understand how these factors affect T cell behavior in the context of cancer. Patients may benefit from insights that could lead to improved CAR T cell therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with relapsed or refractory B-cell malignancies, particularly those undergoing CAR T cell therapy.
Not a fit: Patients with solid tumors or those not eligible for CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR T cell therapies for patients with relapsed and refractory cancers.
How similar studies have performed: Previous research has shown promising results in enhancing CAR T cell therapies through genetic modifications, suggesting that this approach may also yield significant advancements.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Hopkins, Caitlin Rosemary — University of Pennsylvania
- Study coordinator: Hopkins, Caitlin Rosemary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.